Although palliative care use has increased over time among young adults with advanced cancers in the United States, new research led by the American Cancer Society (ACS) found that utilization still remains very low.

Mike Burns is a pharmacist and a small-business owner. He also has been a cancer patient.

You’ve finished your cancer treatment and shown no evidence of disease — for weeks, months or maybe even years. Then, a routine scan or bloodwork reveals something concerning.

I sat terrified and alone atop a gurney, awaiting the scheduled time for my cystectomy, holding a clipboard with forms to complete as the nurse rushed off to do something else.

Cancer rates in recent decades have been declining. Yet from 2010 to 2019, the incidence of 14 cancer types among people under the age of 50 has increased.

It’s not uncommon for breast cancer patients in the rural South to travel hundreds of miles to reach the medical practice run by Dr. Phillip Ley, a cancer surgeon in Jackson, Mississippi.

Clinical trials remain out of reach for many Americans, with only 7% of patients with cancer participating in clinical trials, according to a new report from the American Society of Clinical Oncology’s (ASCO) State of Cancer Care in America series.

Facing a cancer diagnosis can be one of the most stressful times for patients and their loved ones.

Both houses of the Alabama legislature unanimously passed Senate Bill 252 during their session this past spring, with the goal of protecting independent pharmacies from what have been described as predatory business practices by healthcare industry middlemen known as Pharmacy Benefit Managers, or PBMs.

A new paper in the Journal of Clinical and Translational Science finds that travel distance to National Cancer Institute (NCI)-funded sites remains a key barrier for patients wanting to participate in clinical trials or research at these locations.